MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

EST MannKind (MNKD) files automatic mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

Reports Q4 revenue $76.8M, consensus $74.98M. Reports reduced debt principal by $236M; remaining convertible debt of $36M; Year-end 2024 cash, ...

MannKind (MNKD) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago. These figures are adjusted ...

Shares of Mannkind (NASDAQ:MNKD) rose 7% in post-market trading Wednesday after the company issued its Q4 earnings report and a business update. Mannkind (NASDAQ:MNKD) reported a Q4 net profit of ...

MannKind Corp (NASDAQ:MNKD) reported a 31% increase in fourth-quarter revenues, reaching $77 million, and a 43% increase for the full year, totaling $286 million. The company successfully reduced ...

MannKind Corporation announced that it will present data from five studies on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam ...

MNKD opened at $5.77 on Wednesday. The business has a fifty day moving average of $6.06 and a 200 day moving average of $6.26. MannKind has a 52-week low of $3.47 and a 52-week high of $7.63. The ...

MannKind Corporation (MNKD) reported a stronger-than-expected performance for Q4 2024, with earnings per share (EPS) of $0.08, surpassing the forecast of $0.03. Revenue reached $76.77 million ...